Lee Boram, Ha Na-Yeon, Park Hyo-Ju, Kim Ae-Ran, Kwon O-Jin, Cho Jung-Hyo, Shin Seon Mi, Kim Jinsung, Yang Changsop
KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
Division of Digestive Diseases, Department of Internal Korean Medicine, Kyung Hee University Medical Center, Seoul 02447, Republic of Korea.
Healthcare (Basel). 2023 May 17;11(10):1456. doi: 10.3390/healthcare11101456.
The herbal medicine Yukgunja-tang has been widely used for the treatment of functional dyspepsia (FD) in the clinical setting of East Asian traditional medicine. This paper presents a protocol for a randomized, assessor-blind, controlled, multicenter, three-arm parallel clinical trial comparing the effectiveness, safety, and cost-effectiveness of Yukgunja-tang with Pyeongwi-san and usual care. A total of 140 participants with Rome IV-diagnosed FD will be randomly assigned to either the Yukgunja-tang (n = 56), Pyeongwi-san (n = 56), or usual care (n = 28) groups. All participants will be educated on dietary guidelines for FD patients. Participants in the Yukgunja-tang and Pyeongwi-san groups will take investigational products for 6 weeks. All participants will be assessed for clinical parameters at weeks 0, 3, 6, 9, and 24. The primary outcome will be measured on the total dyspepsia symptom scale, and the secondary outcome will include the single dyspepsia symptom scale, overall treatment effect, the visual analog scale for dyspepsia, FD-related quality of life, hospital anxiety and depression scale, EuroQol-5 dimension, pattern identification, and serum levels of acyl-ghrelin and deacyl-ghrelin. Adverse events and laboratory tests will be monitored for safety assessment. The results will provide evidence of the effectiveness, safety, and cost-effectiveness of Yukgunja-tang in the treatment of FD.
草药制剂郁君加汤(Yukgunja-tang)在东亚传统医学的临床环境中已被广泛用于治疗功能性消化不良(FD)。本文介绍了一项随机、评估者盲法、对照、多中心、三臂平行临床试验的方案,该试验比较郁君加汤与平胃散(Pyeongwi-san)及常规护理的有效性、安全性和成本效益。共有140名经罗马IV标准诊断为FD的参与者将被随机分配到郁君加汤组(n = 56)、平胃散组(n = 56)或常规护理组(n = 28)。所有参与者都将接受FD患者饮食指南的教育。郁君加汤组和平胃散组的参与者将服用研究产品6周。所有参与者将在第0、3、6、9和24周接受临床参数评估。主要结局将通过消化不良症状总评分来衡量,次要结局将包括单一消化不良症状评分、总体治疗效果、消化不良视觉模拟量表、FD相关生活质量、医院焦虑抑郁量表、欧洲五维健康量表、证型辨识以及酰基胃泌素和去酰基胃泌素的血清水平。将监测不良事件和实验室检查以进行安全性评估。研究结果将为郁君加汤治疗FD的有效性、安全性和成本效益提供证据。
Evid Based Complement Alternat Med. 2018-10-1
Medicine (Baltimore). 2022-9-2
Medicine (Baltimore). 2020-5-22
Healthcare (Basel). 2024-11-21
Plant Divers. 2022-4-26
Evid Based Complement Alternat Med. 2022-1-29
J Gastroenterol Hepatol. 2021-1
Medicine (Baltimore). 2020-5-22
Korean J Gastroenterol. 2018-10-25
Evid Based Complement Alternat Med. 2018-10-1
United European Gastroenterol J. 2018-2
Gastroenterology. 2016-5
Qual Life Res. 2016-7